IBDEI1XH ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30798,1,4,0)
;;=4^J10.1
;;^UTILITY(U,$J,358.3,30798,2)
;;=^5008151
;;^UTILITY(U,$J,358.3,30799,0)
;;=K52.9^^123^1588^2
;;^UTILITY(U,$J,358.3,30799,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30799,1,3,0)
;;=3^Gastroenteritis & Colitis,Noninfective,Unspec
;;^UTILITY(U,$J,358.3,30799,1,4,0)
;;=4^K52.9
;;^UTILITY(U,$J,358.3,30799,2)
;;=^5008704
;;^UTILITY(U,$J,358.3,30800,0)
;;=N12.^^123^1588^7
;;^UTILITY(U,$J,358.3,30800,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30800,1,3,0)
;;=3^Tubulo-Interstitial Nephritis
;;^UTILITY(U,$J,358.3,30800,1,4,0)
;;=4^N12.
;;^UTILITY(U,$J,358.3,30800,2)
;;=^5015575
;;^UTILITY(U,$J,358.3,30801,0)
;;=L97.509^^123^1588^4
;;^UTILITY(U,$J,358.3,30801,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30801,1,3,0)
;;=3^Non-Pressure Chr Ulcer Unspec Foot w/ Unspec Severity
;;^UTILITY(U,$J,358.3,30801,1,4,0)
;;=4^L97.509
;;^UTILITY(U,$J,358.3,30801,2)
;;=^5009544
;;^UTILITY(U,$J,358.3,30802,0)
;;=M86.10^^123^1588^5
;;^UTILITY(U,$J,358.3,30802,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30802,1,3,0)
;;=3^Osteomylitis,Acute,Unspec Site
;;^UTILITY(U,$J,358.3,30802,1,4,0)
;;=4^M86.10
;;^UTILITY(U,$J,358.3,30802,2)
;;=^5014521
;;^UTILITY(U,$J,358.3,30803,0)
;;=E85.9^^123^1589^1
;;^UTILITY(U,$J,358.3,30803,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30803,1,3,0)
;;=3^Amyloidosis,Unspec
;;^UTILITY(U,$J,358.3,30803,1,4,0)
;;=4^E85.9
;;^UTILITY(U,$J,358.3,30803,2)
;;=^334185
;;^UTILITY(U,$J,358.3,30804,0)
;;=N00.9^^123^1589^3
;;^UTILITY(U,$J,358.3,30804,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30804,1,3,0)
;;=3^Nephritic Syndrome w/ Morphologic Changes,Acute
;;^UTILITY(U,$J,358.3,30804,1,4,0)
;;=4^N00.9
;;^UTILITY(U,$J,358.3,30804,2)
;;=^5015500
;;^UTILITY(U,$J,358.3,30805,0)
;;=N08.^^123^1589^2
;;^UTILITY(U,$J,358.3,30805,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30805,1,3,0)
;;=3^Glomerular Disorders in Diseases Classified Elsewhere
;;^UTILITY(U,$J,358.3,30805,1,4,0)
;;=4^N08.
;;^UTILITY(U,$J,358.3,30805,2)
;;=^5015569
;;^UTILITY(U,$J,358.3,30806,0)
;;=N03.9^^123^1589^4
;;^UTILITY(U,$J,358.3,30806,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30806,1,3,0)
;;=3^Nephritic Syndrome w/ Morphologic Changes,Chronic
;;^UTILITY(U,$J,358.3,30806,1,4,0)
;;=4^N03.9
;;^UTILITY(U,$J,358.3,30806,2)
;;=^5015530
;;^UTILITY(U,$J,358.3,30807,0)
;;=N05.8^^123^1590^1
;;^UTILITY(U,$J,358.3,30807,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30807,1,3,0)
;;=3^Nephritic Syndrome w/ Morphologic Changes,Unspec
;;^UTILITY(U,$J,358.3,30807,1,4,0)
;;=4^N05.8
;;^UTILITY(U,$J,358.3,30807,2)
;;=^5134085
;;^UTILITY(U,$J,358.3,30808,0)
;;=M30.0^^123^1591^2
;;^UTILITY(U,$J,358.3,30808,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30808,1,3,0)
;;=3^Polyarteritis Nodosa
;;^UTILITY(U,$J,358.3,30808,1,4,0)
;;=4^M30.0
;;^UTILITY(U,$J,358.3,30808,2)
;;=^5011738
;;^UTILITY(U,$J,358.3,30809,0)
;;=N04.9^^123^1591^1
;;^UTILITY(U,$J,358.3,30809,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30809,1,3,0)
;;=3^Nephrotic Syndrome w/ Morphologic Changes
;;^UTILITY(U,$J,358.3,30809,1,4,0)
;;=4^N04.9
;;^UTILITY(U,$J,358.3,30809,2)
;;=^5015540
;;^UTILITY(U,$J,358.3,30810,0)
;;=N13.30^^123^1592^2
;;^UTILITY(U,$J,358.3,30810,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30810,1,3,0)
;;=3^Hydronephrosis,Unspec
;;^UTILITY(U,$J,358.3,30810,1,4,0)
;;=4^N13.30
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XH 3787 printed Oct 16, 2024@18:18:30 Page 2
IBDEI1XH ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30798,1,4,0)
+2 ;;=4^J10.1
+3 ;;^UTILITY(U,$J,358.3,30798,2)
+4 ;;=^5008151
+5 ;;^UTILITY(U,$J,358.3,30799,0)
+6 ;;=K52.9^^123^1588^2
+7 ;;^UTILITY(U,$J,358.3,30799,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,30799,1,3,0)
+10 ;;=3^Gastroenteritis & Colitis,Noninfective,Unspec
+11 ;;^UTILITY(U,$J,358.3,30799,1,4,0)
+12 ;;=4^K52.9
+13 ;;^UTILITY(U,$J,358.3,30799,2)
+14 ;;=^5008704
+15 ;;^UTILITY(U,$J,358.3,30800,0)
+16 ;;=N12.^^123^1588^7
+17 ;;^UTILITY(U,$J,358.3,30800,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,30800,1,3,0)
+20 ;;=3^Tubulo-Interstitial Nephritis
+21 ;;^UTILITY(U,$J,358.3,30800,1,4,0)
+22 ;;=4^N12.
+23 ;;^UTILITY(U,$J,358.3,30800,2)
+24 ;;=^5015575
+25 ;;^UTILITY(U,$J,358.3,30801,0)
+26 ;;=L97.509^^123^1588^4
+27 ;;^UTILITY(U,$J,358.3,30801,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,30801,1,3,0)
+30 ;;=3^Non-Pressure Chr Ulcer Unspec Foot w/ Unspec Severity
+31 ;;^UTILITY(U,$J,358.3,30801,1,4,0)
+32 ;;=4^L97.509
+33 ;;^UTILITY(U,$J,358.3,30801,2)
+34 ;;=^5009544
+35 ;;^UTILITY(U,$J,358.3,30802,0)
+36 ;;=M86.10^^123^1588^5
+37 ;;^UTILITY(U,$J,358.3,30802,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,30802,1,3,0)
+40 ;;=3^Osteomylitis,Acute,Unspec Site
+41 ;;^UTILITY(U,$J,358.3,30802,1,4,0)
+42 ;;=4^M86.10
+43 ;;^UTILITY(U,$J,358.3,30802,2)
+44 ;;=^5014521
+45 ;;^UTILITY(U,$J,358.3,30803,0)
+46 ;;=E85.9^^123^1589^1
+47 ;;^UTILITY(U,$J,358.3,30803,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,30803,1,3,0)
+50 ;;=3^Amyloidosis,Unspec
+51 ;;^UTILITY(U,$J,358.3,30803,1,4,0)
+52 ;;=4^E85.9
+53 ;;^UTILITY(U,$J,358.3,30803,2)
+54 ;;=^334185
+55 ;;^UTILITY(U,$J,358.3,30804,0)
+56 ;;=N00.9^^123^1589^3
+57 ;;^UTILITY(U,$J,358.3,30804,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,30804,1,3,0)
+60 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Acute
+61 ;;^UTILITY(U,$J,358.3,30804,1,4,0)
+62 ;;=4^N00.9
+63 ;;^UTILITY(U,$J,358.3,30804,2)
+64 ;;=^5015500
+65 ;;^UTILITY(U,$J,358.3,30805,0)
+66 ;;=N08.^^123^1589^2
+67 ;;^UTILITY(U,$J,358.3,30805,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,30805,1,3,0)
+70 ;;=3^Glomerular Disorders in Diseases Classified Elsewhere
+71 ;;^UTILITY(U,$J,358.3,30805,1,4,0)
+72 ;;=4^N08.
+73 ;;^UTILITY(U,$J,358.3,30805,2)
+74 ;;=^5015569
+75 ;;^UTILITY(U,$J,358.3,30806,0)
+76 ;;=N03.9^^123^1589^4
+77 ;;^UTILITY(U,$J,358.3,30806,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,30806,1,3,0)
+80 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Chronic
+81 ;;^UTILITY(U,$J,358.3,30806,1,4,0)
+82 ;;=4^N03.9
+83 ;;^UTILITY(U,$J,358.3,30806,2)
+84 ;;=^5015530
+85 ;;^UTILITY(U,$J,358.3,30807,0)
+86 ;;=N05.8^^123^1590^1
+87 ;;^UTILITY(U,$J,358.3,30807,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,30807,1,3,0)
+90 ;;=3^Nephritic Syndrome w/ Morphologic Changes,Unspec
+91 ;;^UTILITY(U,$J,358.3,30807,1,4,0)
+92 ;;=4^N05.8
+93 ;;^UTILITY(U,$J,358.3,30807,2)
+94 ;;=^5134085
+95 ;;^UTILITY(U,$J,358.3,30808,0)
+96 ;;=M30.0^^123^1591^2
+97 ;;^UTILITY(U,$J,358.3,30808,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,30808,1,3,0)
+100 ;;=3^Polyarteritis Nodosa
+101 ;;^UTILITY(U,$J,358.3,30808,1,4,0)
+102 ;;=4^M30.0
+103 ;;^UTILITY(U,$J,358.3,30808,2)
+104 ;;=^5011738
+105 ;;^UTILITY(U,$J,358.3,30809,0)
+106 ;;=N04.9^^123^1591^1
+107 ;;^UTILITY(U,$J,358.3,30809,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,30809,1,3,0)
+110 ;;=3^Nephrotic Syndrome w/ Morphologic Changes
+111 ;;^UTILITY(U,$J,358.3,30809,1,4,0)
+112 ;;=4^N04.9
+113 ;;^UTILITY(U,$J,358.3,30809,2)
+114 ;;=^5015540
+115 ;;^UTILITY(U,$J,358.3,30810,0)
+116 ;;=N13.30^^123^1592^2
+117 ;;^UTILITY(U,$J,358.3,30810,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,30810,1,3,0)
+120 ;;=3^Hydronephrosis,Unspec
+121 ;;^UTILITY(U,$J,358.3,30810,1,4,0)
+122 ;;=4^N13.30
